Evaluating High-Flow Nasal Cannula Oxygen Use During Noninvasive Ventilation Breaks After Extubation: Clinical Outcomes from a Multicenter Observational Study

Highlight

This multicenter observational study evaluated the impact of high-flow nasal cannula (HFNC) oxygen compared to standard oxygen during breaks from prophylactic noninvasive ventilation (NIV) in high-risk patients after extubation. While unadjusted analysis indicated a significantly reduced extubation failure rate with HFNC, adjusted analysis using G-computation did not confirm a statistically significant benefit. Reintubation rates were lower within 48 hours with HFNC but converged afterwards, suggesting a potential early advantage that warrants future randomized trials.

Study Background and Clinical Context

Extubation failure in critically ill patients remains a significant clinical challenge, often leading to increased morbidity, mortality, and healthcare resource utilization. Patients classified as high-risk—those aged over 65 years or with underlying cardiac or respiratory diseases—are particularly vulnerable to respiratory deterioration following planned extubation. Prophylactic noninvasive ventilation (NIV) has received guideline support for reducing extubation failure in this cohort. However, the optimal oxygen delivery method during breaks from NIV sessions is uncertain.

High-flow nasal cannula (HFNC) oxygen therapy delivers heated and humidified oxygen at high flow rates, enhancing oxygenation and providing a degree of positive airway pressure. Its use during NIV breaks may help maintain lung recruitment and reduce respiratory muscle load, potentially lowering extubation failure risk. Until now, evidence comparing HFNC with standard oxygen therapy in this clinical context has been limited.

Study Design and Methods

This observational study pooled data from two multicenter clinical trials involving 1077 patients identified as high risk for extubation failure, including those older than 65 years or with cardiac or respiratory comorbidities. All patients received prophylactic NIV immediately after extubation, alternating with either HFNC oxygen (NIV/HFNC group, n=655) or conventional oxygen therapy (NIV/O2 group, n=422) during breaks from NIV sessions.

The primary endpoint was extubation failure, defined as reintubation or death within seven days post-extubation. To estimate the causal effect of HFNC on extubation failure risk while adjusting for confounding factors, the authors employed G-computation, a statistical method that models expected outcomes under different treatment scenarios.

Key Findings

Unadjusted analysis demonstrated that the NIV/HFNC group had a significantly lower rate of extubation failure at day 7 compared to NIV/O2 (13.7% vs. 18.5%; absolute difference -4.7%, 95% CI -9.4% to -0.3%, p=0.036). This corresponds to a modest but clinically relevant reduction in failure rates favoring HFNC.

However, when confounding variables were accounted for using G-computation, the adjusted difference in extubation failure risk with HFNC was -3.9% (95% CI -8.7% to 0.9%), which did not reach statistical significance, indicating that the observed benefit might be partly due to baseline patient differences or other factors.

Regarding secondary outcomes, reintubation rates were significantly lower in the HFNC group within 48 hours after extubation but showed no statistically significant difference beyond 48 hours. This suggests that HFNC may confer early respiratory support benefits during the critical immediate post-extubation period.

Safety outcomes and adverse events were not detailed in the publication abstract, limiting comprehensive assessment, but the absence of reported safety concerns aligns with existing HFNC safety data in post-extubation settings.

Expert Commentary

This study provides valuable real-world evidence regarding oxygen delivery strategies during NIV breaks in high-risk extubated patients. The use of HFNC appears promising to reduce the risk of extubation failure, particularly early reintubation within 48 hours. The physiological rationale includes improved oxygenation, reduced work of breathing, and provision of low-level positive airway pressure that supports alveolar recruitment.

Nevertheless, the lack of statistically significant adjusted benefit underscores inherent limitations of observational data—such as unmeasured confounding and selection bias. Patients receiving HFNC might differ in subtle ways affecting outcomes, and the timing and criteria for extubation and NIV weaning variations across centers could influence results.

Current clinical guidelines recommend prophylactic NIV for high-risk patients, but they do not specify oxygen modalities during NIV interruptions. This study highlights a knowledge gap and lays groundwork for prospective randomized controlled trials to investigate whether HFNC should become standard practice in this setting.

Previous trials in similar populations have shown HFNC to be at least non-inferior and sometimes superior to conventional oxygen after extubation. The unique focus here on oxygen strategy during NIV breaks is notable and clinically relevant for optimizing respiratory support protocols in the intensive care unit.

Conclusion and Future Directions

This large observational study suggests that HFNC oxygen delivered during breaks from prophylactic NIV after extubation may reduce extubation failure rates in high-risk patients, especially early reintubation within 48 hours. Although adjusted analyses tempered enthusiasm by showing no definitive statistically significant effect, findings support the potential benefit of HFNC in this context.

Confirmatory randomized controlled trials are warranted to delineate the efficacy, safety, and cost-effectiveness of HFNC during NIV breaks post-extubation and to guide standardized respiratory management protocols. Optimizing post-extubation respiratory support remains a critical area to reduce morbidity and improve outcomes in vulnerable ICU populations.

Funding and Trial Registration

The included data were derived from two prior multicenter clinical trials led by Thille et al. Specific funding sources are not detailed in the abstract. Trial registration details would need to be consulted from primary trial publications for completeness.

References

1. Thille AW, Chamblet L, Ragot S, et al. High-flow nasal cannula oxygen during breaks from noninvasive ventilation after extubation: an observational study. Intensive Care Med. 2026 Jul 13. PMID: 42440109. https://pubmed.ncbi.nlm.nih.gov/42440109/
2. Stéphan F, Barrucand B, Petit P, et al. High-flow nasal oxygen vs noninvasive ventilation in hypoxemic patients after cardiothoracic surgery: a randomized clinical trial. JAMA. 2015;313(23):2331-9.
3. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185-96.
4. Clinical practice guidelines. Management of patients at risk of extubation failure. Intensive Care Med. 2022;48(10):1512-1528.